Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Nuvation Bio is a clinical-stage biopharmaceutical company developing targeted therapies and immunotherapies for oncology. The company's lead asset, taletrectinib (NUV-422), is a ROS1/TRK inhibitor in Phase 3 trials for ROS1-positive non-small cell lung cancer (NSCLC), targeting a genetically defined patient population with limited treatment options. With no commercial revenue and negative operating margins exceeding -7500%, the stock trades on clinical trial milestones, regulatory catalysts, and partnership potential rather than traditional financial metrics.
Nuvation operates the classic biotech development model: raise capital through equity offerings, invest in clinical trials to generate regulatory approval data, then monetize through either direct commercialization or partnerships with larger pharmaceutical companies. The company's value proposition centers on precision oncology targeting specific genetic mutations (ROS1, TRK, ALK) where patient selection via companion diagnostics enables higher response rates. Pricing power in approved targeted therapies typically ranges $150K-$200K annually given limited competition in rare mutations and high unmet need. The business model requires sustained capital access until FDA approval, with binary risk/reward tied to Phase 3 trial outcomes expected in 2026-2027.
Phase 3 ARROS-1 trial data readouts for taletrectinib in ROS1+ NSCLC (primary endpoint: progression-free survival vs chemotherapy)
FDA regulatory interactions and potential accelerated approval pathway discussions based on objective response rates
Partnership announcements or licensing deals for ex-US commercialization rights or earlier-stage pipeline assets
Clinical trial enrollment milestones and timeline updates for patient recruitment completion
Cash runway updates and equity financing announcements that extend or shorten operational timeline
Binary clinical trial risk: Phase 3 ARROS-1 failure would eliminate primary value driver, as ROS1+ NSCLC represents <2% of lung cancer cases and trial failure leaves limited near-term catalysts
Regulatory approval uncertainty: FDA may require additional safety data, longer follow-up, or post-marketing commitments that delay commercialization beyond current 2027-2028 estimates
Reimbursement pressure: Payers increasingly scrutinize high-cost oncology drugs, and companion diagnostic requirements add complexity to market access even if approved
Pfizer's entrectinib and Roche's rozlytrek already approved for ROS1+ NSCLC, establishing treatment paradigms that taletrectinib must demonstrate superiority against
Next-generation ROS1 inhibitors in development (repotrectinib from Turning Point, others) may offer better CNS penetration or resistance mutation coverage
Large pharma competitors have significantly greater resources for commercialization, market access, and physician education if multiple ROS1 inhibitors reach market
Cash burn of approximately $100M annually with zero revenue creates continuous dilution risk through equity raises, which have driven share count expansion
Current cash runway estimated through 2026-2027 based on burn rate, requiring additional financing before potential product approval and revenue generation
Debt-to-equity of 0.18 is manageable but any convertible debt could create overhang if stock underperforms conversion price
low - Clinical trial timelines and regulatory processes operate independently of GDP cycles. However, severe recessions can impact capital markets access for equity financing, which is critical for pre-revenue biotechs. Patient enrollment may see modest delays during economic stress if healthcare utilization declines, but oncology trials typically maintain priority.
Rising rates create significant headwinds through two mechanisms: (1) Higher discount rates compress NPV of distant future cash flows, disproportionately impacting long-duration assets like clinical-stage biotechs where revenues are 3-5+ years away, and (2) Risk-free rate competition makes speculative growth equities less attractive relative to bonds. The 10-year Treasury yield directly influences biotech valuation multiples. Additionally, higher rates increase the cost of convertible debt financing if the company pursues non-dilutive capital.
Minimal direct exposure - the company is not credit-dependent for operations and maintains high current ratio of 8.48x. However, broader credit market stress can freeze biotech IPO/follow-on markets, limiting capital access. High-yield spreads serve as a proxy for risk appetite that affects speculative equity financing availability.
growth - Pure speculation on binary clinical/regulatory outcomes attracts risk-tolerant growth investors and biotech specialists. The 153% one-year return reflects momentum trading around trial milestones. No dividends, negative earnings, and minimal tangible book value eliminate value and income investors. The investment thesis is entirely forward-looking: successful Phase 3 data could drive 200-300% upside if approval probability rises to 70-80%, while trial failure could result in 60-80% drawdown.
high - Clinical-stage biotechs exhibit extreme volatility around binary events. Single-day moves of 30-50% are common on trial data releases. The 113% six-month return demonstrates momentum characteristics. Institutional ownership is likely concentrated among specialized healthcare funds rather than broad index investors, creating lower liquidity and higher volatility.
